ClinicalTrials.gg
Not yet recruitingNCT03716011Updated Oct 23, 2018

A Postmarket Clinical Trial for EXCROSSAL Stent in CAD Patients With 3-month DAPT or 12-month DAPT

An interventional study of EXCROSSAL in Coronary Artery Disease, sponsored by JW Medical Systems Ltd. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-10-23.

Sponsored by JW Medical Systems Ltd (part of Blue Sail Medical Co., Ltd.) · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2021, 4 years 11 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,700
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Coronary Artery Disease by Blue Sail Medical Co., Ltd. — 8 open to participants now, 11 under way, none of them phase 3. Coronary Artery Disease · Blue Sail Medical Co., Ltd..

Planned enrollment
2nd of 16
2,700 · median 200
Started
2018
with 2 others
No phase
16 of 23
7 open now
Primary completion
2021-12
later than 0 of 10 live
Registered
9th of 23
by date

Among the 23 studies in Coronary Artery Disease by Blue Sail Medical Co., Ltd., this one is the 2nd largest by planned enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2018, is one of 16 with no phase, reaches primary completion later than 0 of the 10 other live ones, and was the 9th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

8 of the 23 studies in Coronary Artery Disease by Blue Sail Medical Co., Ltd. are open now, in 2 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Coronary Artery Disease by Blue Sail Medical Co., Ltd., or all of them as a file.
02

Study summary

  1. Prospective, randomized, multicenter clinical study
  2. This is a post-marketing clinical study to evaluate whether it will affect the safety event when it is used in different treatment ways. Adopting non - inferiority design, 2700 cases were enrolled.
  3. EDC system (eCRF electronic data collection system)
  4. Follow-up points: 30 days,3 months, 12 months, 24 months, 36 months, 48 months and 60 months after the operation;
Read the detailed description
  1. Subjects are eligible for coronary intervention
  2. The lesion needs to be pre-expanded or special circumstances should be carefully considered according to the clinical manifestations
  3. The selection of target vessel is based on the criteria of a diameter between 2.25mm and 4.0mm
  4. If a stent needs to be placed at the target vessel, it is recommended that there be at least 2mm overlap between the stents; if the stent expansion is not sufficient, post-dilatation treatment is required.
03

Conditions studied

  • Coronary Artery Disease
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years and ≤75 years;
  2. De novo coronary artery primary lesions;
  3. Stable angina pectoris;
  4. Patients with coronary artery disease with similar symptoms of myocardial ischemia or angina;
  5. Suitable for PCI indication and suitable for the implant of EXCROSSAL stents.
  6. Able to understand the purpose of the study, voluntarily participate and sign the form, and willing to accept the clinical follow-up; Imaging criteria The target lesion length≤ 60mm;Visual reference diameter of the vessel is 2.25-4.0mm;

Exclusion criteria

Exclusion Criteria:

  1. Patients with acute myocardial infarction (AMI) within 7 days; Non-ST elevated ACS patients
  2. those who implanted any stent before;
  3. Left ventricular ejection score() 30 %
  4. Patients with bleeding tendency or anticoagulation treatment and/or PCI contraindications or coagulopathy;
  5. There are other diseases such as cancer, malignant tumor, congestive heart failure, organ transplant, or candidate) or has a history of abuse (alcohol, cocaine, heroin, etc.), plan adherence is poor, or the of less than 1 year;
  6. It is estimated that elective surgery patients within 12 months;
  7. Other coronary lesions requiring staged intervention;
  8. If there are branches of blood vessels that need to be treated, the diameter of blood vessels ≥ 2.5 mm;
  9. The subject's compliance or the researcher's judgment was not suitable for the participants in the study;
  10. Pregnant or lactating persons; Imaging criteria
  1. Left main disease, transplanted vessel lesions, stent restenosis; 2. The balloon cannot be predilated or/or the severe calcification lesion of rotatory failure; 3. The distortion of the stent is difficult to pass;
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
2,700 participants (estimated)

Study arms

  • Other
    DAPT 3M or DAPT 12M

    After stent implantation in DAPT 3M or DAPT 12M

    Device: EXCROSSAL

Interventions

  • DeviceEXCROSSAL

    a Second Generation Biodegradable Polymer Sirolimus-Eluting Stent

06

What researchers measure

Primary outcomes

  1. Target lesion failure at 12-Month

    The target lesion failure (TLF) rate at 12 months after operation involves cardiac death, target-vessel myocardial infarction, and clinical-symptom driven target vessel revascularization.

    Time frame: 12-month

Secondary outcomes

  1. MACE rate

    Incidence of major adverse cardiac events (MACE) at different follow-up points of 1-month,3-month,6-month,12-month,24-month,36-month,48-month,60-montjh. 2. Stent implantation success rate (covering the device success, the lesion success and the clinical success); 3. Target lesion failure (TLF) at 30 days,3 months, 12 months, 24 months, 36 months, 48 months and 60 months after the operation; 4. Subject-related cardio-clinical composite end points at the follow-up points: 30 days,3 months, 12 months, 24 months, 36 months, 48 months and 60 months after the operation, covering all-cause mortality, all myocardial infarctions and any revascularization; 5. The incidence of ARC-defined stent thrombosis events (defined, probable and non-excludable stent thrombosis in early, late, and delayed stages);

    Time frame: 1-month,3-month,6-month, 12-month, 24-month, 36-month, 48-month and 60-month.

  2. Device success rates , lesion success rates , clinical success rates

    The success of the instrument refers to the degree of stenosis in the final bracket after the instrument was implanted. Lt; 30 %(visual), TIMI level 3 blood flow, and no residual stenosis and thrombus. The success of the lesion refers to the degree of ultimate diameter stenosis of the target lesion after the application of any interventional treatment. 50 %(visual), TIMI level 3 blood flow, and no residual stenosis and thrombus. The success of surgery refers to the absence of major cardiac adverse events caused by ischemia during the patient's hospitalization(up to 7 days after surgery) based on the success of the lesion.

    Time frame: 1-month,3-month,6-month, 12-month, 24-month, 36-month, 48-month and 60-month.

  3. Definite and probable stent thrombosis

    According to ARC definition

    Time frame: 1-month,3-month, 12-month, 24-month, 36-month, 48-month and 60-month.

07

Study locations

1 site
  • JW Medical System
    Beijing, Beijing 100029, China
    • Wei M Fu, Bachelor · Contactwei.fu@jwmsgrp.com · +86 10 50981788
    • Hao M Lu, Ph.D · Contacthaolu04@yahoo.com.cn · +86 10 50981788
    • Junbo M Ge, Ph.D · Principal investigator
    • Lei M Ge, Ph.D · Sub investigator
    • Yong M Huo, Ph.D · Sub investigator
    • Jian an M Wang, Ph.D · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2018; primary completion for Dec 2021, 36 months later.

Of 177 industry-sponsored interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 40. This study's planned 36 months is above that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2018
First posted
Oct 23, 2018
StartEst.
Dec 20, 2018
Primary completionEst.
Dec 20, 2021
CompletionEst.
Dec 20, 2025
Last update
Oct 23, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03716011
Responsible party
Sponsor
First posted
Oct 23, 2018
Start date
Dec 20, 2018 (estimated)
Primary completion
Dec 20, 2021 (estimated)
Completion
Dec 20, 2025 (estimated)
Last update
Oct 23, 2018

Study contacts

Lei M Ge, Ph.D
Contact
ge.lei@zs-hospital.sh.cn
+86 10 50981788 ext. 2
Junbo M Ge, Ph.D
Contact
ge.junbo@zs-hospital.sh.cn
+86 10 50981788 ext. 1
Hao M Lu, Ph.D
study director · Zhongshan hospital of ShangHai FuDan University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion